<DOC>
	<DOCNO>NCT00235105</DOCNO>
	<brief_summary>Reduction sign symptoms patient moderate severely early axial spondyloarthritis ( without radiological sacroiliitis ) inadequate response tolerate NSAID therapy . Study Objectives : Efficacy –To ass whether patient moderate severely active early axial spondyloarthritis ( without radiological sacroiliitis ) show response adalimumab add pre-existing case intolerance NSAID therapy . Response measure week 12 change efficacy parameter compare baseline.Safety – To demonstrate safety adalimumab study patient moderate severely active early axial spondyloarthritis ( without radiological sacroiliitis ) patient inadequate response tolerate NSAID therapy .</brief_summary>
	<brief_title>D2E7-Early AS</brief_title>
	<detailed_description>The study two center 12-week double-blind , placebo-controlled trial adalimumab patient moderate severely active axial spondyloarthritis ( without radiological sacroiliitis ) inadequate response intolerant NSAID therapy . Patients may treat past concomitant DMARDs . For patient washout period least 4 week necessary . If Leflunomide discontinue , stop least 3 month wash within 4 week study start . Patients treat previously approve biologics allow enter study fail due lack efficacy and/or intolerance . The placebo-controlled treatment period 12 week follow open-label maintenance therapy Week 52 . Following screen baseline evaluation , patient assess Weeks 2 , 4 , 8 , 12 . During maintenance therapy visit perform Weeks 16 , 20 every eight week thereafter.Efficacy safety measurement record throughout entire 52 week study.Non-responders ( fail reach ASAS 40 ) week 12 open label therapy ( week 24 ) , eligible adalimumab dose escalation 40 mg weekly.The study follow 24 week follow phase . During period patient assess every eight week .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients 18 year age old moderate severely active axial spondyloarthritis . Diagnosis make : Chronic low back pain ( duration &gt; 3 month , onset &lt; 50 year age ) plus 3 6 follow criterion ( include two follow three criterion : inflammatory back pain , positive HLAB27 positive MRI show acute inflammatory lesion spine ISG ) Inflammatory back pain1 Good good response NSAIDs One follow extraspinal manifestation : uveitis , peripheral arthritis , enthesitis HLAB27 positive Positive MRI show acute inflammatory lesion spine ISG Positive family history SpA Active disease define BASDAI score equal 4 , back pain score ( BASDAI question 2 ) equal 4 despite concurrent NSAID therapy , intolerance NSAIDs . Other inclusion criterion include : If prednisone , equal less 7.5 mg per day ; stable 4 week prior baseline . An evaluation latent tuberculosis infection perform use Mendel Mantoux Test 10TE ( PPD ) , read chest xray , perform within last 12 week inclusion , history exposure infect subject . Patients evidence latent TB infection give prophylaxis accordance local guideline ( Isoniazid 300 mg adequate substitution vitamin B6 9 month 600 mg Rifampicine 6 month ) . The prophylaxis start 4 week adalimumab administer . After 2 week prophylaxis blood test ( liver enzymes , creatinine blood count ) obtain . Patients document prophylaxis past need repeat treatment . Women child bear potential must negative pregnancy test study baseline use adequate method contraception ( include 3 month study completion ) . Sexual active men must use accepted method contraception include 3 month study completion . Able selfadminister injectable drug supply caregiver . Able store injectable test article 2° 8° C. Definite ankylose spondylitis ( accord modify New York criterion , sacroiliitis ³ grade 2 bilaterally grade 3 4 unilaterally ) History active tuberculosis ( TB ) , histoplasmosis listeriosis . History positive HIV status . Positive serology hepatitis B C indicate active infection , case hepatitis B also indicate chronic infection History malignancy carcinoma situ cervix adequately treat nonmetastatic squamous basal cell skin carcinoma . Antibiotic treatment within 3 week prior screen . Treatment biologicals within last 12 week If DMARDs washout period least 4 week necessary . If Leflunomide discontinue , stop least 3 month wash within 4 week study start . History uncontrolled diabetes , unstable ischemic heart disease , active inflammatory bowel disease , active peptic ulcer disease , recent stroke ( within 3 month ) , ongoing congestive heart failure , condition , opinion investigator , would put subject risk participation protocol . Female subject pregnant breastfeeding . Previous diagnosis sign demyelinate disease History systemic lupus erythematosusReceipt live ( attenuate ) vaccine within 4 week screen visit Laboratory exclusion : hemoglobin level &lt; 8,5 mg/dl , white blood cell count &lt; 3.5 x109/l , platelet count &lt; 125 x 109 /l , creatinine level &gt; 175 µmol/liver enzymes alkaline phosphatase &gt; 2 time upper limit normal . Participation trial investigational medication within 30 day enter study Clinical examination show significant abnormality clinical relevance History current evidence abuse ” hard ” drug ( e.g . cocaine/heroine ) alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>early ankylose spondylitis</keyword>
	<keyword>spondyloarthritis</keyword>
	<keyword>trial</keyword>
	<keyword>adalimumab</keyword>
</DOC>